For rheumatologists with busy schedules, staying up to date on the latest research can be difficult. Here are a few tips to help you review and prioritize the literature that could affect your practice…
Drug Makers Inconsistent in Sharing Clinical Trial Data
(Reuters Health)—Drug companies are inconsistent about disclosing data related to clinical trials of new medicines, a new report says. Researchers examined publicly available data on clinical trials for 15 new medicines from 10 companies that were cleared for sale by the U.S. Food and Drug Administration in 2012. Two of the companies disclosed all trials…
U.S. Doctor Group Calls for Ban on Drug Advertising to Consumers
(Reuters)—The American Medical Association on Tuesday called for a ban on advertising prescription drugs and medical devices directly to consumers, saying the ads drive patients to demand expensive treatments over less costly ones that are also effective. The influential doctors’ group said the new policy reflects physicians’ concerns that marketing spending on a proliferation of…
Autoimmune Diseases Common in Patients with Vitiligo
NEW YORK (Reuters Health)—Patients with vitiligo commonly have other autoimmune diseases, according to a cross-sectional study. “Vitiligo is a systemic disease with multiple comorbidities,” Dr. Iltefat Hamzavi from Henry Ford Hospital in Detroit, Mich., told Reuters Health by email. “The number of patients with neurologic diseases and inflammatory disease was much higher than we anticipated.”…
Advocate for Rheumatology with the ACR
Your voice is an essential part of the ACR’s advocacy efforts, and our new Legislative Action Center makes contacting your legislator easier than ever before…
FDA Approves 2 Pain Drugs & New Gout Treatment on Road to Approval
The FDA has approved two drugs designed to manage pain: buprenorphine for chronic pain and meloxicam capsules for OA pain. Lesurinad is also closer to FDA approval for treating gout…
Obama Nominee to Lead FDA Defends Drug Industry Ties
(Reuters)—President Barack Obama’s nominee to head the U.S. Food and Drug Administration defended his ties to the pharmaceutical industry on Tuesday during a Senate committee hearing that included questions on soaring drug prices. Presidential candidate Bernie Sanders was among the Democrats who grilled Dr. Robert Califf (64), who joined the FDA in January as a…
WHO Warns of Widespread Misunderstanding of Superbug Threat
LONDON (Reuters)—People across the world are confused about the major threat to public health posed by drug-resistant superbugs and do not know how to stop that risk growing, the World Health Organization (WHO) said on Monday. Ramping up its fight against antibiotic resistance with a survey of public awareness, the United Nations health agency said…
Diagnostic Clues, Tips Useful for Differentiating RA and Lyme Disease
RA vs. Lyme I am writing to comment on your interesting and useful article that appeared on the front page of the August issue of The Rheumatologist, “RA vs. Lyme,” by Charles Radis, DO. Arriving at a definite diagnosis of active RA early on is often not an easy task. The author of this article…
Legal Issues Around Retiring, Shuttering Your Medical Practice
You worked hard your entire life to build your medical practice, and now you’re ready to enjoy retirement. Regardless of whether you choose to sell your practice or gradually wind it down over a period of time, you must take certain legal steps before you can leave. Deciding to Retire & Making a Plan Once…
- « Previous Page
- 1
- …
- 534
- 535
- 536
- 537
- 538
- …
- 809
- Next Page »